Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ZEENAT SAFDAR

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1669532891
CMS profile
210987
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$51,923.53

81 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ZEENAT SAFDAR

NPI 1669532891 · CMS profile ID 210987

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669532891?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ZEENAT SAFDAR, NPI 1669532891, CMS profile ID 210987. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669532891?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ZEENAT SAFDAR, NPI 1669532891, CMS profile ID 210987. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669532891?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ZEENAT SAFDAR, NPI 1669532891, CMS profile ID 210987, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1669532891?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

81 matching records · $51,923.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 81 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–81 of 81.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Actelion Pharmaceuticals US, Inc. $144.2204/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078917085 CMS
Actelion Pharmaceuticals US, Inc. $108.3304/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078917023 CMS
United Therapeutics Corporation $6,000.0004/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149460720 CMS
United Therapeutics Corporation $6,000.0004/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149476278 CMS
Actelion Pharmaceuticals US, Inc. $545.0004/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078917117 CMS
United Therapeutics Corporation $88.0704/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149446950 CMS
United Therapeutics Corporation $563.6404/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149461256 CMS
United Therapeutics Corporation $267.9804/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149461128 CMS
Actelion Pharmaceuticals US, Inc. $4,050.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078917249 CMS
Actelion Pharmaceuticals US, Inc. $473.8503/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078917915 CMS
Actelion Pharmaceuticals US, Inc. $100.0003/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078917723 CMS
Actelion Pharmaceuticals US, Inc. $5.5003/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078917179 CMS
ABBVIE INC. $14.6003/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105998769 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.0003/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118102985 CMS
United Therapeutics Corporation $48.8903/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149447894 CMS
United Therapeutics Corporation $479.9703/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149476034 CMS
United Therapeutics Corporation $35.0003/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149476517 CMS
United Therapeutics Corporation $66.5502/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149475727 CMS
United Therapeutics Corporation $2,500.0002/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149461840 CMS
Insmed, Inc. $23.6702/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089578304 CMS
Actelion Pharmaceuticals US, Inc. $37.0602/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078917493 CMS
United Therapeutics Corporation $89.0202/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149446682 CMS
ABBVIE INC. $13.1801/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105998767 CMS
AstraZeneca Pharmaceuticals LP $18.4901/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105518471 CMS
United Therapeutics Corporation $58.7201/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149460726 CMS
United Therapeutics Corporation $58.7801/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149460918 CMS
United Therapeutics Corporation $144.2301/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149461696 CMS
Actelion Pharmaceuticals US, Inc. $7.6301/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078917077 CMS
PFIZER INC. $16.9401/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131828110 CMS
GlaxoSmithKline, LLC. $22.2001/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116318284 CMS
Johnson & Johnson Health Care Systems Inc. $14.4801/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077573294 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $46,189.87 87
PY2020 $29,704.66 29
PY2021 $30,618.34 33
PY2022 $32,445.91 64
PY2023 $71,083.39 116
PY2024 $51,923.53 81
PY2025 $29,152.13 66

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $200,644.78 42
PY2024 Principal investigator $196,682.14 29
PY2023 Principal investigator $273,359.50 18
PY2022 Principal investigator $357,247.12 28
PY2021 Principal investigator $134,082.42 25
PY2020 Principal investigator $132,574.51 14
PY2019 Principal investigator $114,069.87 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $11,160.00 12/17/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389147
Principal investigator 1 United Therapeutics Corporation $3,645.00 12/15/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389095
Principal investigator 1 Merck Sharp & Dohme LLC $26,899.86 12/10/2025 Non-covered Recipient Entity
Houston Methodist Hospital
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH No dispute reported 06/30/2026 1232917565
Principal investigator 1 United Therapeutics Corporation $1,182.00 12/05/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389089
Principal investigator 1 United Therapeutics Corporation $11,793.60 11/20/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389111
Principal investigator 1 United Therapeutics Corporation $1,593.00 11/19/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389135
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,470.00 11/05/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799928
Principal investigator 1 United Therapeutics Corporation $9,370.60 10/16/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389107
Principal investigator 1 United Therapeutics Corporation $3,591.40 10/16/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389141
Principal investigator 1 United Therapeutics Corporation $200.00 10/02/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389085
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $313.56 09/24/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799938
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $213.00 09/24/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799940
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $131.10 09/24/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799942
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $65.50 09/24/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799944
Principal investigator 1 United Therapeutics Corporation $4,527.90 09/22/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389097
Principal investigator 1 United Therapeutics Corporation $503.10 09/22/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389127
Principal investigator 1 United Therapeutics Corporation $958.00 09/11/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389133
Principal investigator 1 United Therapeutics Corporation $140.00 09/10/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389125
Principal investigator 1 United Therapeutics Corporation $7,546.50 08/13/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389103
Principal investigator 1 United Therapeutics Corporation $503.10 08/13/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389129
Principal investigator 1 United Therapeutics Corporation $7,043.40 07/18/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389101
Principal investigator 1 United Therapeutics Corporation $4,456.80 07/18/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389145
Principal investigator 1 United Therapeutics Corporation $1,418.92 07/16/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389091
Principal investigator 1 United Therapeutics Corporation $10,689.30 06/18/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389109
Principal investigator 1 United Therapeutics Corporation $2,993.40 06/18/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389137
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,985.00 06/04/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799936
Principal investigator 1 United Therapeutics Corporation $15,076.80 05/20/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389115
Principal investigator 1 United Therapeutics Corporation $4,604.40 05/14/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389099
Principal investigator 1 United Therapeutics Corporation $3,496.50 05/14/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389139
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $852.00 05/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799932
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $262.00 05/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799934
Principal investigator 1 United Therapeutics Corporation $3,999.60 04/18/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389143
Principal investigator 1 United Therapeutics Corporation $9,132.30 04/14/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389105
Principal investigator 1 United Therapeutics Corporation $56.00 04/11/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389123
Principal investigator 1 United Therapeutics Corporation $12,791.70 03/21/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389113
Principal investigator 1 United Therapeutics Corporation $586.80 03/19/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389131
Principal investigator 1 United Therapeutics Corporation $56.00 02/21/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389121
Principal investigator 1 United Therapeutics Corporation $23,824.50 02/19/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389117
Principal investigator 1 United Therapeutics Corporation $904.00 02/05/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389087
Principal investigator 1 United Therapeutics Corporation $56.00 02/05/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242389119
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,570.00 02/03/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799930
Principal investigator 1 United Therapeutics Corporation $1,982.14 01/22/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242389093